Rethinking Clinical Trial KPIs: From ‘First Participant, First Visit’ to Last ‘Participant, Last Visit’

In the clinical trials industry, Key Performance Indicators (KPIs) have long been dominated by the ‘First Participant, First Visit’ (FPFV) metric. Sponsors, CROs, and sites alike celebrate the speed at which a trial enrolls its first participant as a major milestone. While there’s no denying that FPFV represents momentum and is often a key financial milestone, there’s growing concern that overemphasis on this single point in time creates a narrow view of trial success, potentially overshadowing more meaningful outcomes further down the line.

The Problem with FPFV-Centric KPIs

FPFV is easy to measure, tangible, and feels like a quick win. However, it only captures the very beginning of a complex process with many variables and risks. The ultimate goal of any trial is not how fast you enroll the first participant - it’s whether the study reaches completion with high-quality data, on time and within budget. Milestones like ‘Last Participant, Last Visit’ (LPLV) and database lock reflect the true value delivered to sponsors, regulators, and, ultimately, participants.

Focusing too heavily on FPFV can unintentionally drive behaviors that prioritize speed over quality and drive geographical and site level selection strategy. Sites may rush through setup or enrolment procedures, compromising compliance, protocol adherence, and possibly impacting data quality and integrity. Similarly, early enrolment-focused KPIs may skew resource allocation and participant screening activities leaving later-stage trial operations under-supported or the trial struggling to find adequate participant numbers to meet recruitment targets, In other words, by celebrating the first participant too loudly, we risk ignoring the ‘long tail’ of trial success and the ultimate goal of finishing on time and on target.

Shifting the Lens to Quality and Competence

The question then becomes: how do we as an industry drive focus and investment in site operations so that LPLV and database lock are seen as equally or more valuable than FPFV? The answer lies in redefining KPIs to balance speed with competence and quality.

1. Broaden Performance Metrics Instead of too singular a focus on FPFV, implement a more balanced portfolio of KPIs that track ongoing site performance to include participant recruitment and retention rates, protocol compliance metrics, query resolution times, and data quality indicators. By monitoring these continuously, we shift attention from the initial milestone to the sustained operational excellence that ensures trials reach LPLV efficiently and with high-quality data.

2. Invest in Achieving Operational Excellence and Workforce Excellence High-quality clinical trial conduct depends on more than simply meeting minimum training requirements, it requires trained, compliant, competent and confident site teams who understand not only the protocol, but the broader operational and ethical responsibilities of research delivery. Equally important is the embedding of quality-driven, best-practice operating processes and procedures that underpin consistent and sustainable trial performance. Robust SOPs, clear governance structures, efficient data management systems, and well-defined participant recruitment and engagement pathways are not administrative extras; they are critical enablers of reliable delivery. Investing in workforce competence alongside clinical and business operational excellence creates the infrastructure for long-term success. When people’s capability and process maturity align, sites are empowered to operate efficiently across the full trial lifecycle, making the achievement of LPLV and database lock not just feasible, but predictable.

3. Encourage Longitudinal Accountability Sponsors and CROs can foster a culture of accountability by connecting incentives to the entire trial lifecycle rather than just early enrollment. Recognition programs, milestone-based bonuses, or performance dashboards that highlight ongoing data quality and retention can reinforce behaviors aligned with full trial success.

4. Leverage the latest Technology for Real-time Insights Modern clinical trials generate vast amounts of operational and clinical data. Leveraging real-time analytics allows teams to identify bottlenecks, monitor participant adherence, and flag protocol deviations early. These insights help sites stay on track to meet LPLV and database lock milestones, shifting focus from a single early victory to sustained excellence.

Conclusion: Balancing Speed with Value and Sustainable Success

FPFV will always matter, it signals readiness, momentum, and critical initial engagement with participants as a primary KPI. But the industry would be wise to recognize that it’s only the starting line, not the finish line. True value in clinical trials is realized when participants complete their participation, data is clean and verified, and the trial achieves database lock efficiently. By broadening KPIs, investing in site competence, fostering longitudinal accountability, and leveraging technology, we can reorient our focus toward these meaningful endpoints.

Continuing the Conversation on Sustainable Trial Success

As the clinical trials landscape continues to evolve, so too must the way we define and measure success. Moving beyond a single milestone such as FPFV does not diminish its importance, but rather places it within a broader context, one that recognises the complexity, responsibility, and long-term commitment required to deliver high-quality research.

Across the industry, there is increasing recognition that sustainable performance comes from strong foundations: competent and confident clinical research professionals, robust operational processes, and governance structures that support both quality and agility. When these elements are embedded, milestones such as LPLV and database lock become the natural outcome of consistent, well-supported practice rather than recovery efforts late in a study.

Organisations like the International Accrediting Organization for Clinical Research (IAOCR) have emerged in response to this growing need for structured frameworks that strengthen both workforce capability and operational maturity. Initiatives such as GCSA – The Global Quality Standard for Clinical Research Sites reflect a broader industry movement toward recognising that excellence in clinical research is built over time, through shared quality standards and global best practices, collaboration, and a commitment to continuous improvement.

Ultimately, the conversation is not about replacing one KPI with another. It is about ensuring that our measures of success genuinely reflect what matters most: ethical conduct, participant trust, high-quality data, and the reliable delivery of studies that advance science and improve lives.

If you would like to learn more about how IAOCR can support your site or site work to achieve business operational and workforce excellence please visit: https://iaocr.com/en/services-for-clinical-trial-sites

Or contact

Vicki Booth - Director of Marketing and Partnerships vbooth@iaocr.com www.IAOCR.com